Skip to main content
$23.61 -$1.29 (-5.2%)

01:01 PM EDT on 05/30/23

Enanta Pharmaceuticals (NASDAQ:ENTA)

CAPS Rating: No stars

Current Price $23.61 Mkt Cap $524.1M
Open $24.85 P/E Ratio -4.16
Prev. Close $24.89 Div. (Yield) $0.00 (0.0%)
Daily Range $23.42 - $25.07 Volume 85,402
52-Wk Range $23.03 - $76.36 Avg. Daily Vol. 197,003

Caps

How do you think NASDAQ:ENTA will perform against the market?

Add Stock to CAPS Watchlist

All Players

75 Outperform
3 Underperform
 

All-Star Players

17 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ENTA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Thrifty1 (< 20)
Submitted April 13, 2014

Royalty stream from abbvie likely significant. tiny company with 44 employees and low cash burn rate. Hep C drug looks like it works. They won't be first to market, but probably will have impact.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:ENTA Summary

Fools bullish on NASDAQ:ENTA are also bullish on:

Fools bearish on NASDAQ:ENTA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ENTA.

Recs

2
Member Avatar Thrifty1 (< 20) Submitted: 4/12/2014 11:17:34 PM : Outperform Start Price: $33.99 NASDAQ:ENTA Score: -160.00

Royalty stream from abbvie likely significant. tiny company with 44 employees and low cash burn rate. Hep C drug looks like it works. They won't be first to market, but probably will have impact.

Recs

1
Member Avatar dbajack2 (86.26) Submitted: 2/10/2014 4:06:30 PM : Outperform Start Price: $38.28 NASDAQ:ENTA Score: -171.34

About to break resistance.

Recs

1
Member Avatar PharmTeam (58.96) Submitted: 12/18/2013 10:29:23 AM : Outperform Start Price: $30.66 NASDAQ:ENTA Score: -157.56

Enanta's collaboration with Abbvie on a next gen HepC treatment is clearly its main growth driver. That drug will face some serious competition from Gilead's Sovaldi, but with pretty comparable cure rates it will be up to payers to decide which drug to go with. Gilead's solid results today sent ENTA down 14% to a market cap of only 500M and change, making for a good entry point.

Leaderboard

Find the members with the highest scoring picks in ENTA.

Score Leader

fredvaldez88

fredvaldez88 (< 20) Score: +262.24

The Score Leader is the player with the highest score across all their picks in ENTA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
CocaineOrStock 94.47 7/15/2014 Underperform 5Y $38.88 -39.04% +112.95% +152.00 0 Comment
PeakingDuck 78.66 6/27/2019 Underperform 5Y $83.38 -71.58% +44.08% +115.65 0 Comment
sikiliza < 20 10/28/2019 Underperform 5Y $59.36 -60.07% +38.72% +98.79 0 Comment
stereotyp72 69.17 4/5/2021 Outperform 5Y $51.20 -53.71% +4.16% -57.87 0 Comment
portefeuille4 98.66 9/2/2016 Outperform 5Y $22.12 +7.17% +92.69% -85.52 0 Comment
superstar2 98.54 7/6/2016 Outperform 5Y $23.19 +2.20% +100.75% -98.55 0 Comment
RonaldSpeth1 55.98 10/25/2016 Outperform 5Y $24.93 -4.93% +95.73% -100.66 0 Comment
TMFConan 84.89 10/3/2016 Outperform 5Y $26.60 -10.90% +94.71% -105.62 0 Comment
Momentum21 48.78 1/31/2017 Outperform 5Y $32.83 -27.81% +85.52% -113.33 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 35.94 7/19/2013 Outperform 5Y $17.56 +34.97% +148.51% -113.54 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ENTA.